About this trial
This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.
Eligibility criteria
Qualifiers
ECOG performance status 0-1 or KPS ≥ 70%
Age ≥ 18 years
Endometrioid adenocarcinoma histologic diagnosis on endometrial biopsy or dilatation and curettage
No evidence of extrauterine disease, or suspicious pelvic lymph nodes, or distant metastases, or cervical invasion on pre-operative conventional imaging studies (Pelvic +/- Abdomen CT or MRI or sonogram, or body PET scan) and physical examination (uterine confined by exam and imaging )
Disqualifiers
Extrauterine disease, or gross lymph node involvement, or cervical invasion suspected on pre-operative imaging studies and physical examination (disease not uterine confined clinical stage > I)
Contraindication for SLN mapping
The planned treatment is not surgery, or the surgical treatment does not include hysterectomy in combination with SLN biopsy and a bilateral salpingo-oophorectomy
Hysterectomy
Trial design
Treatments tested in this trial
- Physical exam